SEOM guidelines for the management of Malignant Melanoma 2015

被引：5

作者：

Berrocal, A. ^{[1
]}

Arance, A. ^{[2
]}

Espinosa, E. ^{[3
]}

Castano, A. G. ^{[4
]}

Cao, M. G. ^{[5
]}

Larriba, J. L. G. ^{[6
]}

Martin, J. A. L. ^{[7
]}

Marquez, I. ^{[8
]}

Soria, A. ^{[9
]}

Algarra, S. M. ^{[10
]}

机构：

[1] Univ Valencia, Med Oncol Serv, Consorcio Hosp Gen, Avda Tres Cruces 2, Valencia 46014, Spain

[2] Hosp Clin Barcelona, Barcelona, Spain

[3] Hosp Univ La Paz, Madrid, Spain

[4] Hosp Univ Marques Valdecilla, Santander, Spain

[5] Hosp Univ Quiron Dexeus, Barcelona, Spain

[6] Hosp Univ Clin San Carlos, Madrid, Spain

[7] Hosp Univ 12 Octubre, Madrid, Spain

[8] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[9] Hosp Univ Ramon & Cajal, Madrid, Spain

[10] Univ Navarra Clin, Pamplona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2015年 / 17卷 / 12期

关键词：

Melanoma; Metastatic; Adjuvant; Immunotherapy; b-raf; COOPERATIVE-ONCOLOGY-GROUP; HIGH-RISK MELANOMA; ADJUVANT THERAPY; CUTANEOUS MELANOMA; POOLED ANALYSIS; OPEN-LABEL; BRAF; INTERFERON; DABRAFENIB; IPILIMUMAB;

D O I：

10.1007/s12094-015-1450-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.

引用

页码：1030 / 1035

页数：6

共 50 条

[1] SEOM guidelines for the management of Malignant Melanoma 2015
A. Berrocal
A. Arance
E. Espinosa
A. G. Castaño
M. G. Cao
J. L. G. Larriba
J. A. L. Martín
I. Márquez
A. Soria
S. M. Algarra
[J]. Clinical and Translational Oncology, 2015, 17 : 1030 - 1035
[2] SEOM clinical guideline for the management of malignant melanoma (2017)
A. Berrocal
A. Arance
V. E. Castellon
L. de la Cruz
E. Espinosa
M. G. Cao
J. L. G. Larriba
I. Márquez-Rodas
A. Soria
S. M. Algarra
[J]. Clinical and Translational Oncology, 2018, 20 : 69 - 74
[3] SEOM clinical guideline for the management of malignant melanoma (2017)
Berrocal, A.
Arance, A.
Castellon, V. E.
de la Cruz, L.
Espinosa, E.
Cao, M. G.
Larriba, J. L. G.
Marquez-Rodas, I.
Soria, A.
Algarra, S. M.
[J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (01): : 69 - 74
[4] MALIGNANT-MELANOMA - MANAGEMENT GUIDELINES
BROZENA, SJ
WATERMAN, G
FENSKE, NA
[J]. GERIATRICS, 1990, 45 (06) : 55 - &
[5] Seom guidelines for the treatment of gastric cancer 2015
Martin-Richard, M.
Custodio, A.
Garcia-Giron, C.
Gravalos, C.
Gomez, C.
Jimenez-Fonseca, P.
Manzano, J. L.
Pericay, C.
Rivera, F.
Carrato, A.
[J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (12): : 996 - 1004
[6] SEOM guidelines for the treatment of malignant pleural mesothelioma
Lianes, Pilar
Remon, Jordi
Bover, Isabel
Isla, Dolores
[J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (08): : 569 - 573
[7] Seom guidelines for the treatment of gastric cancer 2015
M. Martin-Richard
A. Custodio
C. García-Girón
C. Grávalos
C. Gomez
P. Jimenez-Fonseca
J. L. Manzano
C. Pericay
F. Rivera
A. Carrato
[J]. Clinical and Translational Oncology, 2015, 17 : 996 - 1004
[8] SEOM guidelines for the treatment of malignant pleural mesothelioma
Pilar Lianes
Jordi Remon
Isabel Bover
Dolores Isla
[J]. Clinical and Translational Oncology, 2011, 13 : 569 - 573
[9] Erratum to: SEOM guidelines for the treatment of gastric cancer 2015
M. Martin-Richard
A. Custodio
C. García-Girón
C. Grávalos
C. Gomez
P. Jimenez-Fonseca
J. L. Manzano
C. Pericay
F. Rivera
A. Carrato
[J]. Clinical and Translational Oncology, 2016, 18 : 426 - 426
[10] SEOM clinical guidelines in metastatic breast cancer 2015
J. Gavilá
S. Lopez-Tarruella
C. Saura
M. Muñoz
M. Oliveira
L. De la Cruz-Merino
S. Morales
I. Alvarez
J. A. Virizuela
M. Martin
[J]. Clinical and Translational Oncology, 2015, 17 : 946 - 955

← 1 2 3 4 5 →